Pregled bibliografske jedinice broj: 1128770
Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study
Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study // PLoS One, 16 (2021), 4; e0249862, 14 doi:10.1371/journal.pone.0249862 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1128770 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Topical NAVS naphthalan for the treatment of oral
lichen planus and recurrent aphthous stomatitis: A
double blind, randomized, parallel group study
Autori
Andabak Rogulj, Ana ; Alajbeg Žilić, Iva ; Brailo, Vlaho ; Škrinjar, Ivana ; Žužul, Ivona ; Vučićević Boras, Vanja ; Alajbeg, Ivan
Izvornik
PLoS One (1932-6203) 16
(2021), 4;
E0249862, 14
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
NAVS naphthalan ; oral lichen planus ; recurrent aphthous stomatitis
Sažetak
Aim To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment of OLP and RAS. Methods The study consisted of two sub-trials conducted as randomized, double-blind controlled studies: first included OLP patients and second patients with RAS. Patients received either NAVS or 0.05% betamethasone dipropionate. Primary outcomes were activity score (OLP patients), No of lesions and lesion diameter (RAS patients) and pain intensity (VAS) while secondary outcome included the impact of the disease on quality of life assessed by Oral health impact profile (OHIP 14). Results No significant differences in terms of OLP clinical signs (p = 0.84, η2 = 0.001) and responses on the OHIP-14 (p = 0.81, η2 = 0.002) or on VAS (p = 0.14, η2 = 0.079) between NAVS and betamethasone groups were observed. In RAS patients, no significant differences between the groups in terms of lesion number (at days 3 and 5, p = 0.33 and p = 0.98, respectively), lesion diameter (days 3 and 5, p = 0.24 and p = 0.84, respectively) were observed. However, in NAVS group a significant reduction of lesions diameter was observed on the 3rd day, while in betamethasone group a significant reduction in lesions diameter was evident only after the 5th day. No significant differences in VAS (p > 0.05) and the OHIP-14 (p > 0.05) between groups were found. Conclusion No evidence of differences between the two compared interventions was found.
Izvorni jezik
Engleski
Znanstvena područja
Dentalna medicina
POVEZANOST RADA
Projekti:
IP-2019-04-6211 - Povezanost genskih polimorfizama s temporomandibularnim poremećajima (GenPolTMD) (Alajbeg, Iva, HRZZ - 2019-04) ( CroRIS)
Ustanove:
Stomatološki fakultet, Zagreb
Profili:
Ivan Alajbeg
(autor)
Ivana Škrinjar
(autor)
Ana Andabak Rogulj
(autor)
Vlaho Brailo
(autor)
Iva Alajbeg
(autor)
Vanja Vučićević Boras
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE